It has begun: Foxconn amassing army of workers for iPhone 18 Pro assembly

appleinsider - Months ahead of the fall launches, and historically right on time, Apple supply chain partner Foxconn has started to hire a small army of assemblers to build the iPhone 18 Pro.Workers at a Foxconn facility - Image source: FoxconnEach summer, the Apple sup…

AI Summary: Agenus has suspended the BATTMAN clinical trial and announced a follow‑on program called ROBBIN after strategic reassessment, a move that has raised questions about transparency and participant communication. The abrupt pivot highlights tensions between rapid corporate decision‑making and the need to maintain patient trust in oncology research.

#healthcare #pharmaceuticals #biotech #drugdevelopment #oncology #cancerresearch #researchfunding #clinicaltrials

3 days / appleinsider

5 days / oncodaily


Back to Top / Sat, July 25, 2026, 11:21 pm / permalink 27688 / 2 stories in 1 hr /




Related Stories


Nine‑year CheckMate‑214 follow‑up confirms durable immunotherapy benefit / 21 days

Teclistamab shows survival benefit prompting earlier use discussions / 5 wks

CAR-PRISM trial shows BCMA CAR T effective in high-risk smoldering myeloma / 3 months

Long‑term immunotherapy appears safe for alveolar soft part sarcoma / 3 months

Zongertinib emerges as first-line therapy for HER2‑mutant NSCLC / 3 months

New mechanism may explain why many cancer drugs fail / 3 months

Antoni Ribas receives AACR‑Margaret Foti Award for leadership / 3 months

StackHealth RSS


You can now follow topics by RSS - browse the complete list of topics, people, and organizations. Or, try Adolescent Health, Clinical Trials, Gene Therapy, Pfizer and look for the RSS link.





NorthFeed Inc. Terms and Conditions / Privacy Policy

Disclaimer: The information provided on this website is intended for general informational purposes only. While we strive for accuracy, we do not guarantee the completeness or reliability of the content. Users are encouraged to verify all details independently. We accept no liability for errors, omissions, or any decisions made based on this information.